TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04139382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Consultation
Description: A telephone consultation comprising clinical history, contraception planning, explanation of medical method of abortion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-Face Consultation
Description: A face-to-face consultation comprising clinical history, contraception planning, explanation of medical method of abortion
Study: NCT01024153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active video game play
Description: Children will get a Wii video game console and one game at week one and another at week 7. We will monitor their video game play and physical activity during this time.
Study: NCT00581477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa Oral Product
Description: Droxidopa administered in increasing dosages up to 300 mg
Study: NCT01968889

Intervention type: OTHER
Intervention: Non invasive phrenic nerve stimulation
Description: Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
Study: NCT00667394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
Study: NCT03909737

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to pregnant women
Description: Placebo to pregnant women at antenatal care visits and during delivery
Study: NCT00667394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN-518 (Tandutinib)
Description: Tandutinib 500 mg by mouth daily dose twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN-518 (Tandutinib)
Description: Tandutinib 500 mg by mouth daily dose twice a day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.
Study: NCT02838992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit ATG, (Genzyme)
Description: ATG is an infusion of rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG, (Genzyme)
Description: ATG is an infusion of rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cy
Description: Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CsA
Description: CsA is an immunosuppressant drug widely used in organ transplantation to prevent rejection. It reduces the activity of the immune system by interfering with the activity and growth of T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA
Description: CsA is an immunosuppressant drug widely used in organ transplantation to prevent rejection. It reduces the activity of the immune system by interfering with the activity and growth of T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord blood
Description: Cord blood is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders
Study: NCT00332462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Sandimmun® i.v.)
Description: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Sandimmun® Optoral)
Description: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
Study: NCT02377167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheostomy
Description: Tracheostomy is performed as percutaneous dilatative tracheostomy with tracheostomy kit by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheostomy
Description: Tracheostomy is performed as percutaneous dilatative tracheostomy with tracheostomy kit by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
Study: NCT01735175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LA-EP2006
Description: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta®
Description: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
Study: NCT04974762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Surgical wound infiltration by proceduralist

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Truncal blocks
Description: Truncal blocks provided by anesthesiology team for device placement
Study: NCT03689777

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: sleeve gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass
Description: gastric bypass
Study: NCT03867539

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Differing pain management strategy
Description: The investigators aim to investigate an alternative (vs standard) pain management strategy for post operative carpal tunnel release. All drugs used are FDA approved for these indications, and no drug itself is being investigated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Differing pain management strategy
Description: The investigators aim to investigate an alternative (vs standard) pain management strategy for post operative carpal tunnel release. All drugs used are FDA approved for these indications, and no drug itself is being investigated.
Study: NCT01931098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Taken .25 mg orally, daily continuous until progression up to one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Taken .25 mg orally, daily continuous until progression up to one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: 600 mg orally, daily until progression, up to one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: 600 mg orally, daily until progression, up to one year.
Study: NCT01712061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04634817
Description: Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
Study: NCT04011007

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy with or without inverted ILM flap technique
Description: vitrectomy without ILM peeling versus vitrectomy with inverted ILM flap technique in cases of macular hole retinal detachment in high myopic eyes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy with or without inverted ILM flap technique
Description: vitrectomy without ILM peeling versus vitrectomy with inverted ILM flap technique in cases of macular hole retinal detachment in high myopic eyes.
Study: NCT01049438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal mupirocin
Description: twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical 3% hexachlorophene body wash
Description: daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral anti-MRSA antibiotic
Description: The choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior MRSA isolates in a given patient
Study: NCT04192110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretic initiation or augmentation
Description: The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
Study: NCT02019186

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: \<30 kg 250 mg 30-60 kg 500 mg \>60 kg 750 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: \<30 kg 100 IU, 30-60 kg 200 IU, \>60 kg 300 IU
Study: NCT05256615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30-minute walking intervention
Description: Participants are asked to go for a 30 minute walk once per day at any time except the 1 hour after a meal. During these walks they are asked to record heart rate using a heart rate monitor and a phone application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30-minute walking intervention
Description: Participants are asked to go for a 30 minute walk once per day at any time except the 1 hour after a meal. During these walks they are asked to record heart rate using a heart rate monitor and a phone application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-minute
Description: Participants are asked to go for a 10-minute walk after each meal occurring 3 times daily. During these walks they are asked to record heart rate using a heart rate monitor and a phone application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-minute
Description: Participants are asked to go for a 10-minute walk after each meal occurring 3 times daily. During these walks they are asked to record heart rate using a heart rate monitor and a phone application.
Study: NCT03119545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beardslee family centered intervention
Description: The method entails six meetings. The time for the meeting is 1-2 hours and is usually held once per week. Meetings 1 and 2) include only the parents and focus firstly on the ill parent's history and secondly on the well parent/relative. Meeting 3) includes interviews with each child aged 6-19 years, without the parents being present, concerning the child´s understanding of the disease, potential worries and questions. During the interview the child can formulate his or her own questions for the family meeting. Meeting 4) includes the parents and focuses on the planning of the family meeting. The child's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5) is the family meeting. Meeting 6) is a follow-up with all of the family members.
Study: NCT03909737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to infants
Description: Placebo to infants at 6 and 14 week EPI visits

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to infants
Description: Placebo to infants at 6 and 14 week EPI visits

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to infants
Description: Placebo to infants at 6 and 14 week EPI visits

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention to pregnant women
Description: No intervention to pregnant women

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention to pregnant women
Description: No intervention to pregnant women
Study: NCT05529888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
Study: NCT02108769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yogic Breathing
Description: 1. Chanting Om~   1. Sharp deep inhalation through nostrils~  2. Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.~   Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.~2. Yogic Breathing:~   1. Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.~  2. Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.~  3. Hold breath in this position for about 16 seconds.~  4. Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.~  5. Go to step a).
Study: NCT01882803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Phosphoinositide-3-kinase (PI3K) inhibitor
Study: NCT03270033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 0.4 millilitres (mL) of 10 milligram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 0.4 millilitres (mL) of 10 milligram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 0.5 millilitres (mL) of 100 microgram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 0.5 millilitres (mL) of 100 microgram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
Study: NCT04388124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03445403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offset analgesia
Description: Exposure to a moderate heat-pain stimulus applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds using a computerized paradigm in order to evoke endogenous pain modulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offset analgesia
Description: Exposure to a moderate heat-pain stimulus applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds using a computerized paradigm in order to evoke endogenous pain modulation.
Study: NCT03743025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide Injection
Description: Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
Study: NCT04095325

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided erector spinae block
Description: Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided erector spinae block
Description: Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
Study: NCT03672344

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lookware TM
Description: Lookware TM is a computer-based video game that requires the subject engage in social skills related exercises that include certain visual behaviors. These exercises combine techniques from applied behavior analysis (ABA) and use of gaze-contingent eye tracking technology during simulated social interactions with 3D animated characters to target certain social skills deficits in children with autism spectrum disorder (ASD). The game is delivered through a laptop computer, eye tracker, and game controller.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lookware TM Control Module
Description: Lookware TM Control Module is a version of the Lookware TM computer-based video game that excludes the social skills related exercises. The game is delivered through a laptop computer, eye tracker, and game controller.
Study: NCT01014078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Ophthalmic Solution, 1%
Description: 1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
Study: NCT02108769

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The participants will read a text of their choice for 20 minutes in a one-on-one session with the Yoga Instructor.
Study: NCT05133492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Stabilization Treatment (EAST)
Description: Endovascular procedure: an ipsilateral ilio-femoral aortogram to confirm suitability for placement of a 14F sheath will be performed. A baseline contrast aortogram will be performed to assess vessel patency and target location of the EAST delivery catheter. Occluding and Stabilizer balloons are inflated in preparation for Stabilizer Compound delivery within the AAA sac. A post-Stabilizer angiogram will re-assess vessel patency and aorta stability. Delivery catheter is removed and discarded. The entire procedure is approximately one hour.
Study: NCT02875197

Intervention type: OTHER
Intervention: Running on a treadmill at 6 different speeds
Description: All subjects will be required to run at 6 prescribed speeds (2.5, 3.0, 3.5, 4.0, 5.0, and 6.0 m/sec) on a treadmill completing at least 10 consecutive strides, or running for 30 seconds.

Intervention type: OTHER
Intervention: Running on a treadmill at 6 different speeds
Description: All subjects will be required to run at 6 prescribed speeds (2.5, 3.0, 3.5, 4.0, 5.0, and 6.0 m/sec) on a treadmill completing at least 10 consecutive strides, or running for 30 seconds.
Study: NCT04537533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Intraoperative infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Intraoperative infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: intravenous infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: intravenous infusion
Study: NCT04544059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 \[capped at 2.0 mg\], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
Study: NCT02105285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-1085EL ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carteolol long-acting ophthalmic solution
Study: NCT04110899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of paratracheal force
Description: An esophageal stethoscope is inserted into the upper esophagus under the application of different paratracheal force in anesthetized and paralyzed patients.
Study: NCT03724045

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Back Side of the Moon
Description: The procedures are: several measurements will be performed, including some which are not part of the Standard Operating Procedure, hence causing it to be considered interventional.~Follow-up during consultation on pneumology until max. 6 months post-admission on the ICU.
Study: NCT02122315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy plus dry needling
Description: Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Best-evidence physical therapy intervention
Study: NCT02681458

Intervention type: OTHER
Intervention: Direct Examination
Description: It was an observational study and subjects received their routine treatment.

Intervention type: OTHER
Intervention: Direct Examination
Description: It was an observational study and subjects received their routine treatment.